The corporate venture arm of a large pharmaceutical company is mandated to invest directly in private early-stage life science companies with promising new products that may be future pipeline candidates. The firm seeks to invest across the more expansive business footprint of its parent company. The firm has a global mandate and is currently seeking new equity investment opportunities.

The firm is particularly interested in therapies for rare diseases, oncology, vaccines, and immune mediated diseases. The firm will also invest in breakthrough product candidates in other therapeutic areas such as cardiovascular and diabetes.  The firm seeks products that are in preclinical or early clinical development and that have proof-of-concept data. The firm also willing to consider medical devices targeting these indication

The firm generally co-invests with top tier life science investors and looks to take a minority position (<20%) in each portfolio company. The firm seeks to be a long-term investor with board responsibilities either as a full seat or as an observer.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The Corporate Venture arm of a Hi-Tech Company current manages a total of $850 million in assets, and is looking to make equity investments ranging from $2-$5 million with the ability to allocate up to $10 million generally in series A-C rounds. The majority of fund’s investment have been throughout the United States although they have and are willing to invest internationally as well. The fund is actively reviewing new opportunities can could make 3-4 investments over the next year.

The Fund is currently interested in sectors of Medical Devices, Diagnostics and Healthcare IT that increase connectivity in the healthcare ecosystem. The fund is particularly interest in verticals of Health and Wellness, Chronic Disease Care, Aging in Place, Telemedicine, Genomics, Patient Monitoring, Clinical Trails Management, Mobile Software Healthcare IT Applications, and Electronic Medical Records Management. The fund is willing to invest in devices with 510k pathways however the fund is not currently considering highly invasive medical devices.

The Fund is looking for privately held companies with experienced management teams. The fund generally looks to take a board or observer seat following investment and is willing to both lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An Ireland-based angel group has been operating for 5 years and has invested a total of €15-20 million in 15-20 companies, of which have raised more than €40 million thus far. The group focuses on the life science industry where they have made their largest investments, while also having several deals in other sectors such as energy and social media. The group seeks to make 3-4 investments a year, with an annual investment size of €3-5 million. The group typically invests €500,000-€1 million per company. The group has done syndicates with Scotland in the past, and is potentially open to syndicating with Angels in other locations. The group typically makes investments in Ireland-based companies, though is looking to make new investments in other regions in Europe, USA, and Australia.

The group has a particular focus in medical devices, and is also open to diagnostics, drug delivery, and drug repackaging. The group will not invest in therapeutics, pharmaceuticals, or new small molecules, and is agnostic in terms of phase of development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Taiwan-based investment firm is an evergreen fund and is the venture capital arm of a listed Taiwanese pharmaceutical company. The firm makes direct equity investments into venture stage companies, typically in Series A and B. The initial allocation ranges from $1-5 million. The firm is currently seeking opportunities based in Taiwan, China, Europe and the US.

The firm focuses 50% on therapeutics, 30% on medical devices, and 20% on other health technology. Within therapeutics, the firm considers small molecules and biologics in Oncology, CNS, pain, rare disease, and anti-infectives. The firm typically invests in preclinical projects that have proof-of-concept data and are within 2 years prior to phase 1 trial. Within medical devices, the firm is interested in innovative minimally invasive surgical tools for patient or bedside use such as point-of-care diagnostics.

The firm is looking for experienced management teams with strong scientific expertise and management skills. The firm typically requests a board seat in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a multinational engineering company is headquartered in Germany with offices in Israel and the United States. The firm’s investments are focused on financial returns, as well as, bringing strategic value to the parent company. The firm makes equity investments in seed through growth rounds ranging from €1M-€5M for typical investments and may invest up to €10M-€12M over the life of the investment. The firm will lead, co-lead or follow and typically seeks a 10%-25% stake in the company. The firm is currently investing out of its second fund of €150M with a total of €350M AUM, and makes 4-6 investments per year. The firm focuses on North American, European and Israeli companies.

The firm is only interested in diagnostics and monitoring devices with a particular interest in point-of-care diagnostics. Recent investments include an autonomous, mobile robot with delivery tracking software and a PCR-based diagnostic instrument for rapid pathogen detection. The firm does not invest in traditional biopharma therapeutics and/or medical devices which require FDA approval.

The firm will work with all management teams, including first time entrepreneurs, and requires at least an observatory board seat with most investments requiring a standard board seat with voting rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An early-stage investment firm is based in Midwestern US and consists of a team of entrepreneurs experienced in the grind of starting, operating, growing and harvesting exciting companies. The firm is investing from a $23M fund closed in 2014. The firm typically participates in institutional rounds and makes equity investments ranging from $250K-$750K in technology companies in $500K-$2M financing rounds. Convertible notes can be made in less frequent occasions.

Roughly 75% of the businesses the firm looks at are located in the Mountain West, and 25% are outside of the region. The firm seeks to lead a financing round in locally based businesses, but it typically plays a minor role in investment outside of their region unless there is a strong fit and local lead. The firm is currently seeking new opportunities.

Within healthcare, the firm is interested in health technologies that are easy to scale and require a short or no regulatory pathway to market. Examples include genomic analytics, physician-patient interphase platform, mobile health, and medical device with a heavy software component. The firm prefers post-concept projects with recurring revenue of 20-60K/month or some market validation.

The firm is looking for experienced management teams with proven profitability. The firm’s team brings in operational expertise and expects to get involved. The firm is open to both leading and co-investing, and if leading is the case, the firm typically takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment group is based in Northeastern United States and invests on behalf of family offices and institutions, and makes direct investments in a variety of sectors including healthcare & life science. Investments in early-stage companies are typically in the form of equity, whereas debt investments in later-stage companies may be considered. The firm’s allocations are highly variable but are generally over $1m, and are typically at least $3m. The firm primarily invests in US-based companies but Canada-based and other international companies may also be considered.

Within the life science sector the firm has diverse interests, with a primary focus on healthcare services companies, including biotech R&D services and healthcare IT services. The firm is also interested in medical devices in late-stage clinical trials, or which are already approved. Investments in therapeutic drug development may be considered but only at later stages (Phase II or later).

The firm seeks to invest in solid management teams who are developing a product based on proprietary, patented technology which addresses a large market need. While the firm may consider investments in pre-revenue companies, they require that a company have a defined path to revenues and will be profitable within three years.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com